Quadrature Capital Ltd Buys Shares of 48,764 LifeStance Health Group, Inc. (NASDAQ:LFST)

Quadrature Capital Ltd purchased a new stake in LifeStance Health Group, Inc. (NASDAQ:LFST) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 48,764 shares of the company’s stock, valued at approximately $341,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Point72 Asset Management L.P. lifted its stake in LifeStance Health Group by 24.9% in the third quarter. Point72 Asset Management L.P. now owns 1,100,441 shares of the company’s stock valued at $7,703,000 after buying an additional 219,329 shares during the period. Parkman Healthcare Partners LLC bought a new stake in shares of LifeStance Health Group in the 3rd quarter valued at about $3,150,000. Paloma Partners Management Co bought a new stake in shares of LifeStance Health Group in the 3rd quarter valued at about $176,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of LifeStance Health Group by 10.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 516,819 shares of the company’s stock valued at $3,618,000 after acquiring an additional 48,634 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in LifeStance Health Group by 31.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,105 shares of the company’s stock worth $169,000 after acquiring an additional 5,767 shares during the last quarter. 85.50% of the stock is currently owned by institutional investors.

Insider Transactions at LifeStance Health Group

In other LifeStance Health Group news, Director Robert Bessler sold 75,000 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $7.54, for a total transaction of $565,500.00. Following the sale, the director now directly owns 1,424,447 shares of the company’s stock, valued at $10,740,330.38. The trade was a 5.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 6.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. UBS Group cut their target price on shares of LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating on the stock in a report on Thursday, August 15th. Barclays increased their price target on LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.50.

LifeStance Health Group Trading Up 1.2 %

LFST opened at $7.43 on Tuesday. The stock has a market capitalization of $2.84 billion, a P/E ratio of -28.58 and a beta of 1.28. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19. LifeStance Health Group, Inc. has a 12 month low of $4.64 and a 12 month high of $9.20. The firm’s fifty day simple moving average is $7.14 and its 200 day simple moving average is $6.29.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.05. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. The company had revenue of $312.70 million during the quarter, compared to analysts’ expectations of $302.25 million. During the same period in the prior year, the firm earned ($0.17) earnings per share. LifeStance Health Group’s revenue for the quarter was up 18.9% compared to the same quarter last year. As a group, research analysts anticipate that LifeStance Health Group, Inc. will post -0.2 EPS for the current fiscal year.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.